A PILOT STUDY OF PENTOXIFYLLINE IN REDUCING SYSTEMIC INFLAMMATION AND IMPROVING

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项前瞻性、单中心、单臂、开放标签、试点研究，评估了戊氨酰茶碱（PTX）的潜在疗效和安全性，PTX是一种磷酸二酯酶抑制剂，可阻断肿瘤坏死因子-β 1的表达。(TNF-?),在印第安纳州大学医学中心观察到的12名HIV感染患者中，CD 4细胞计数大于350/L，目前未接受抗逆转录病毒治疗，入组受试者将在基线时以及PTX治疗4周和8周后再次测量肱动脉血流介导的扩张（FMD）（内皮功能的测量）和其他心血管和免疫学参数。 每例受试者将接受约10周的随访。本研究的总持续时间约为8个月。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective, single center, single arm, open-label, pilot study evaluating the potential efficacy and safety of pentoxifylline (PTX), a phosphodiesterase inhibitor that blocks tumor necrosis factor-? (TNF-?), in the treatment of endothelial dysfunction in twelve HIV-infected patients seen at the Indiana University Medical Center with CD4 cell counts greater than 350/¿L and not currently receiving antiretroviral therapy. Enrolled subjects will have their brachial flow-mediated dilation (FMD), a measure of endothelial function, and other cardiovascular and immunologic parameters measured at baseline and again after 4 and 8 weeks of treatment with PTX. Each individual subject will be followed for approximately 10 weeks. The total duration of this study will be approximately 8 months.